Vaccine Development: How 2bind Used Accelerated Stability Studies To Optimize An Antigen For HIV-Vaccine Research
Source: NanoTemper Technologies, Inc.
Join Dr. Thomas Schubert, CEO of 2bind, as he walks through information from the Prometheus Panta that helped them select the optimal buffer for a vaccine antigen.
You’ll learn about:
- Why 2bind required both thermal and colloidal stability information to identify the optimal buffer for antigen stability out of a 96 condition screen
- Which stress conditions they assessed to probe the limits of antigen stability in the selected buffer, and how DLS helped them do it
- How they further used DLS to validate epitope integrity and antibody binding to the antigen
- How the group used a single instrument to conduct all their experiments for buffer optimization
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online
X
Subscribe to Drug Discovery Online
NanoTemper Technologies, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more